User login
Key clinical point: Agomelatine appeared to be an effective preventive treatment for episodic migraine without aura.
Major finding: After 3 months of treatment, patients receiving agomelatine vs placebo had significant reduction in headache frequency (4.8 vs 5.82; P = .009) and severity (─4.1 vs ─0.71; P < .001), mean monthly migraine days (8.86 vs 10.63; P = .025), and Migraine Disability Assessment Score (MIDAS; ─1.06 vs ─0.36; P < .001).
Study details: Findings are from a parallel randomized controlled trial that included 99 patients with episodic migraine without aura who were randomly assigned to receive either agomelatine (n = 49) or placebo (vitamin B1 tablets; n = 50).
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Farzin K et al. The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study. BMC Neurol. 2024;24:2 (Jan 2). doi: 10.1186/s12883-023-03516-9
Key clinical point: Agomelatine appeared to be an effective preventive treatment for episodic migraine without aura.
Major finding: After 3 months of treatment, patients receiving agomelatine vs placebo had significant reduction in headache frequency (4.8 vs 5.82; P = .009) and severity (─4.1 vs ─0.71; P < .001), mean monthly migraine days (8.86 vs 10.63; P = .025), and Migraine Disability Assessment Score (MIDAS; ─1.06 vs ─0.36; P < .001).
Study details: Findings are from a parallel randomized controlled trial that included 99 patients with episodic migraine without aura who were randomly assigned to receive either agomelatine (n = 49) or placebo (vitamin B1 tablets; n = 50).
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Farzin K et al. The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study. BMC Neurol. 2024;24:2 (Jan 2). doi: 10.1186/s12883-023-03516-9
Key clinical point: Agomelatine appeared to be an effective preventive treatment for episodic migraine without aura.
Major finding: After 3 months of treatment, patients receiving agomelatine vs placebo had significant reduction in headache frequency (4.8 vs 5.82; P = .009) and severity (─4.1 vs ─0.71; P < .001), mean monthly migraine days (8.86 vs 10.63; P = .025), and Migraine Disability Assessment Score (MIDAS; ─1.06 vs ─0.36; P < .001).
Study details: Findings are from a parallel randomized controlled trial that included 99 patients with episodic migraine without aura who were randomly assigned to receive either agomelatine (n = 49) or placebo (vitamin B1 tablets; n = 50).
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Farzin K et al. The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study. BMC Neurol. 2024;24:2 (Jan 2). doi: 10.1186/s12883-023-03516-9